ARQT — Arcutis Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $3.38bn
- $3.26bn
- $376.07m
Brief: Arcutis Presents Late-Breaking Data From Integument-Ped Phase 3 Trial Of Roflumilast Cream
U.S. STOCKS ON THE MOVE-Boeing, Chemours, C3.ai
U.S. STOCKS ON THE MOVE-Voyager Therapeutics, GoodRx Holdings, Tenet Healthcare
Arcutis Biotherapeutics drops on $150 mln stock deal
Brief: Arcutis Announces Pricing Of $150 Million Public Offering
Brief: Arcutis Announces Proposed Public Offering
Brief: Arcutis And Sato Announce Strategic Collaboration And Licensing Agreement For Topical Roflumilast In Japan
Arcutis Biotherapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Arcutis Biotherapeutics Q4 basic EPS USD -0.72
Arcutis Biotherapeutics Inc expected to post a loss of 77 cents a share - Earnings Preview
Arcutis Biotherapeutics Inc expected to post a loss of 78 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Biomarin Pharmaceutical, Intuit, Penumbra
Brief: Arcutis Biotherapeutics Files For Mixed Shelf Of Upto $300 Million - SEC Filing
Brief: Steven Cohen Reports 5.2% Passive Stake In Arcutis Biotherapeutics As Of Jan 30, 2024 - SEC Filing
U.S. STOCKS ON THE MOVE-Macy's, Spirit Airlines, Gilead Sciences
Arcutis Biotherapeutics rises on eczema drug launch
Brief: Arcutis Biotherapeutics Says Majority Of Individuals With Co's Atopic Dermatitis Improved Roflumilast Cream 0.15%
Brief: Arcutis Biotherapeutics Says Zoryve Topical Foam, 0.3% Clears Seborrheic Dermatitis
Brief: Arcutis Canada Announces Health Canada Acceptance Of The Supplement To A New Drug Submission For Roflumilast